Trial record 1 of 1 for:    WVU 11310
Previous Study | Return to List | Next Study

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by West Virginia University
Sponsor:
Information provided by (Responsible Party):
West Virginia University
ClinicalTrials.gov Identifier:
NCT01203020
First received: September 13, 2010
Last updated: November 4, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2018
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)